Melbourne-based Imugene Ltd announced in January 2022 the receipt of the company’s FY21 R&D Tax Offset refund of $6,541,921.
The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including:
In recent years the market capitalisation of Imugene Ltd has increased significantly to over $2 Billion AUD.
Receipt of refundable R&D tax offsets of this magnitude reduces the need for a company to raise additional capital to complete trials, and make pathway to commercialisation exponentially easier.
To see if your company is eligible for the R&D Tax Offset, fill out our eligibility form here.